By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Investing > FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment
Investing

FDA advisers vote in favor of Biogen and Eisai’s collaborative Alzheimer’s treatment

News Room
Last updated: 2023/06/10 at 10:52 AM
By News Room
Share
3 Min Read
SHARE

Advisers to the U.S. Food and Drug Administration on Friday voted unanimously in favor of the Eisai Co. Ltd. and Biogen Alzheimer’s treatment Leqembi, saying that a clinical study had verified its benefit.

Eisai
ESALF,
+9.35%
shares jumped on the news and finished the day up 9.4%. Biogen
BIIB,
+1.31%
stock trading was halted Friday during the advisory committee meeting.

Leqembi, also known as lecanemab, is a monoclonal antibody designed to reduce the buildup of amyloid beta plaque in the brain, a hallmark of Alzheimer’s disease. 

The treatment in January got a green light under the FDA’s accelerated approval program, which allows for earlier approval of drugs that treat serious conditions even while studies to confirm the anticipated clinical benefit are ongoing. If those trials show that the drug actually provides a clinical benefit, the FDA grants traditional approval for the drug. An FDA decision on traditional approval is expected by July 6. Advisory committee votes are not binding, but the FDA often follows committee recommendations.

About 6.7 million people 65 and older in the U.S. are living with Alzheimer’s dementia, according to the Alzheimer’s Association. Alzheimer’s was the fifth-leading cause of death among people 65 and older in 2019, according to the association. 

Traditional approval of Leqembi, which has a sticker price of $26,500 per year, could have a significant impact on Medicare spending. If Leqembi and similar new Alzheimer’s treatments are granted traditional approval, the Centers for Medicare and Medicaid Services said last week that Medicare would cover the treatments in cases where the beneficiary’s doctor and clinical team participate in collecting real-world evidence about how the drugs are working — a system known as a registry. 

If 5% of the older adults with Alzheimer’s disease take Leqembi, annual Medicare Part B spending would jump by about $8.9 billion, according to a recent analysis by health policy nonprofit KFF. The increased spending would likely lead to higher Part B premiums, according to the analysis.

During the open public hearing portion of the FDA meeting Friday, several experts raised concerns that the difference in cognitive outcomes for patients treated with Leqembi seemed small and emphasized safety issues identified in the clinical trials, including potential brain swelling or bleeding. “Patients and their families deserve better than false hope,” Patricia Bencivenga, special projects coordinator for PharmedOut, a research and education project at Georgetown University Medical Center, told the committee.

Other public commenters emphasized the value of any slowing in Alzheimer’s patients’ decline. “The additional time provided by these treatments is clear,” Joanne Pike, president and CEO of the Alzheimer’s Association, told the committee. “The value of this time is also clear when you listen directly to those who would benefit.”

Read the full article here

News Room June 10, 2023 June 10, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
‘El Chapo’ scion pleads guilty to US drug trafficking charges

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Fuel to Air India 171’s engines was cut off seconds before fatal crash, report says

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Kraft Heinz explores potential break-up

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Elon Musk’s xAI seeks up to $200bn valuation in next fundraising

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Trump’s immigration agenda follows the trade template — for good and ill

Unlock the White House Watch newsletter for freeYour guide to what Trump’s…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Nursing Home Stocks Could Suffer from this Medicaid Spending Remedy

By News Room
Investing

Bitcoin Drops Below $90,000 Again. What Could Move It Next.

By News Room
Investing

These Stocks Are Moving the Most Today: Marvell, Nvidia, Broadcom, GM, Tesla, MongoDB, Burlington, and More

By News Room
Investing

Nvidia Stock Falls as Marvell Earnings Compound AI Gloom. The Rising Risks for Chips.

By News Room
Investing

This analyst says Tesla deliveries will be 16% below expectations. Musk is part of the problem.

By News Room
Investing

BP CEO was awarded no bonus pay from oil giant’s financial performance

By News Room
Investing

Shares of Starlink’s European competitor have tripled. CEO says it can do the job in Ukraine.

By News Room
Investing

GE Vernova Stock Rises as Analyst Flips to Upgrade After Rating Cut

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?